| Treatment of advanced thyroid cancer with targeted therapies: ten years of experience D Viola, L Valerio, E Molinaro, L Agate, V Bottici, A Biagini, L Lorusso, ... Endocrine-related cancer 23 (4), R185-R205, 2016 | 225 | 2016 |
| Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at a single Italian center E Molinaro, MC Campopiano, L Pieruzzi, A Matrone, L Agate, V Bottici, ... The Journal of Clinical Endocrinology & Metabolism 105 (3), e172-e180, 2020 | 168 | 2020 |
| Targeted therapy in thyroid cancer: state of the art L Valerio, L Pieruzzi, C Giani, L Agate, V Bottici, L Lorusso, V Cappagli, ... Clinical oncology 29 (5), 316-324, 2017 | 159 | 2017 |
| Twenty-five years experience on RET genetic screening on hereditary MTC: an update on the prevalence of germline RET mutations R Elisei, A Tacito, T Ramone, R Ciampi, V Bottici, V Cappagli, D Viola, ... Genes 10 (9), 698, 2019 | 109 | 2019 |
| New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double RET mutations C Romei, F Casella, A Tacito, V Bottici, L Valerio, D Viola, V Cappagli, ... Journal of medical genetics 53 (11), 729-734, 2016 | 99 | 2016 |
| Obesity as a risk factor for thyroid cancer A Matrone, F Ferrari, F Santini, R Elisei Current Opinion in Endocrinology, Diabetes and Obesity 27 (5), 358-363, 2020 | 78 | 2020 |
| Thyroid cancers: from surgery to current and future systemic therapies through their molecular identities L Lorusso, V Cappagli, L Valerio, C Giani, D Viola, L Puleo, C Gambale, ... International Journal of Molecular Sciences 22 (6), 3117, 2021 | 74 | 2021 |
| Postoperative Thyroglobulin and Neck Ultrasound in the Risk Restratification and Decision to Perform 131I Ablation A Matrone, C Gambale, P Piaggi, D Viola, C Giani, L Agate, V Bottici, ... The Journal of Clinical Endocrinology & Metabolism 102 (3), 893-902, 2017 | 70 | 2017 |
| Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer? C Romei, A Tacito, E Molinaro, L Agate, V Bottici, D Viola, A Matrone, ... Clinical Endocrinology 82 (6), 892-899, 2015 | 68 | 2015 |
| Efficacy and safety of long-term management of patients with chronic post-surgical hypoparathyroidism A Meola, E Vignali, A Matrone, F Cetani, C Marcocci Journal of Endocrinological Investigation 41 (10), 1221-1226, 2018 | 64 | 2018 |
| Changing Trend of Thyroglobulin Antibodies in Patients With Differentiated Thyroid Cancer Treated With Total Thyroidectomy Without 131I Ablation A Matrone, F Latrofa, L Torregrossa, P Piaggi, C Gambale, A Faranda, ... Thyroid 28 (7), 871-879, 2018 | 53 | 2018 |
| Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience C Romei, A Tacito, E Molinaro, P Piaggi, V Cappagli, L Pieruzzi, ... Oncology letters 15 (6), 9174-9182, 2018 | 52 | 2018 |
| Differentiated thyroid cancer, from active surveillance to advanced therapy: toward a personalized medicine A Matrone, MC Campopiano, A Nervo, G Sapuppo, M Tavarelli, S De Leo Frontiers in endocrinology 10, 884, 2020 | 49 | 2020 |
| Sporadic medullary thyroid carcinoma: towards a precision medicine A Matrone, C Gambale, A Prete, R Elisei Frontiers in endocrinology 13, 864253, 2022 | 48 | 2022 |
| Ultrasound features and risk stratification systems to identify medullary thyroid carcinoma A Matrone, C Gambale, M Biagini, A Prete, P Vitti, R Elisei European Journal of Endocrinology 185 (2), 193-200, 2021 | 47 | 2021 |
| Effects of tyrosine kinase inhibitors on thyroid function and thyroid hormone metabolism A Basolo, A Matrone, R Elisei, F Santini Seminars in Cancer Biology 79, 197-202, 2022 | 46 | 2022 |
| Prevalence and risk factors of developing fistula or organ perforation in patients treated with lenvatinib for radioiodine-refractory thyroid cancer L Valerio, C Giani, L Agate, E Molinaro, D Viola, V Bottici, A Matrone, ... European thyroid journal 10 (5), 399-407, 2021 | 43 | 2021 |
| Potential impact of BMI on the aggressiveness of presentation and clinical outcome of differentiated thyroid cancer A Matrone, G Ceccarini, M Beghini, F Ferrari, C Gambale, M D’Aqui, ... The Journal of Clinical Endocrinology & Metabolism 105 (4), e1124-e1134, 2020 | 39 | 2020 |
| Somatic RET Indels in Sporadic Medullary Thyroid Cancer: Prevalence and Response to Selpercatinib R Elisei, R Ciampi, A Matrone, A Prete, C Gambale, T Ramone, ... The Journal of Clinical Endocrinology & Metabolism 107 (8), 2195-2202, 2022 | 37 | 2022 |
| Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response L Valerio, V Bottici, A Matrone, P Piaggi, D Viola, V Cappagli, L Agate, ... Endocrine-Related Cancer 27 (2), 97-110, 2020 | 36 | 2020 |
Paolo PiaggiNational Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of HealthVerified email at nih.gov
